fulvestrant

Also known as ICI 182,780

Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.

Key facts

Drug.Verifiedfields: changed
Drug.Watchedfields: changed
Drug.verifiedrevid: 410130476
Drug.image: Fulvestrant.svg
Drug.image_class: skin-invert-image
Drug.width: 250
Drug.tradename: Faslodex, others
Drug.MedlinePlus: a607031
Drug.DailyMedID: Fulvestrant
Drug.pregnancy_AU: D
Drug.routes_of_administration: Intramuscular injection
Drug.class: Antiestrogen
Drug.ATC_prefix

Article

17 sections

Contents

Medical uses
Breast cancer
Early puberty
Available forms
Contraindications
Side effects
Pharmacology
Pharmacodynamics
Pharmacokinetics
Chemistry
Synthesis
History
Society and culture
NICE evaluation
Patent extension
Research
References

Fulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it.